Indivior Pharmaceuticals, Inc. (INDV)
34.47
-0.86
(-2.43%)
USD |
NASDAQ |
Oct 23, 16:00
34.48
+0.01
(+0.03%)
After-Hours: 20:00
Indivior Pharmaceuticals Enterprise Value : 4.354B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 4.354B |
| October 22, 2026 | 4.456B |
| October 21, 2026 | 4.392B |
| October 20, 2026 | 4.390B |
| October 19, 2026 | 4.284B |
| October 16, 2026 | 4.116B |
| October 15, 2026 | 4.254B |
| October 14, 2026 | 4.318B |
| October 13, 2026 | 4.467B |
| October 12, 2026 | 4.542B |
| October 09, 2026 | 4.515B |
| October 08, 2026 | 4.470B |
| October 07, 2026 | 4.550B |
| October 06, 2026 | 4.523B |
| October 05, 2026 | 4.534B |
| October 02, 2026 | 4.501B |
| October 01, 2026 | 4.462B |
| September 30, 2026 | 4.517B |
| September 29, 2026 | 4.605B |
| September 28, 2026 | 4.639B |
| September 25, 2026 | 4.514B |
| September 24, 2026 | 4.535B |
| September 23, 2026 | 4.524B |
| September 22, 2026 | 4.557B |
| September 21, 2026 | 4.480B |
| Date | Value |
|---|---|
| September 18, 2026 | 4.403B |
| September 17, 2026 | 4.498B |
| September 16, 2026 | 4.340B |
| September 15, 2026 | 4.325B |
| September 14, 2026 | 4.354B |
| September 11, 2026 | 4.357B |
| September 10, 2026 | 4.359B |
| September 09, 2026 | 4.390B |
| September 08, 2026 | 4.337B |
| September 04, 2026 | 4.410B |
| September 03, 2026 | 4.397B |
| September 02, 2026 | 4.423B |
| September 01, 2026 | 4.365B |
| August 31, 2026 | 4.409B |
| August 28, 2026 | 4.402B |
| August 27, 2026 | 4.452B |
| August 26, 2026 | 4.514B |
| August 25, 2026 | 4.531B |
| August 24, 2026 | 4.556B |
| August 21, 2026 | 4.638B |
| August 20, 2026 | 4.745B |
| August 19, 2026 | 4.894B |
| August 18, 2026 | 4.940B |
| August 17, 2026 | 4.898B |
| August 14, 2026 | 4.890B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Supernus Pharmaceuticals, Inc. | 2.035B |
| Eli Lilly & Co. | 1.245T |
| Bristol Myers Squibb Co. | 159.59B |
| Liquidia Corp. | 3.699B |
| Harmony Biosciences Holdings, Inc. | 1.653B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 122.00M |
| Revenue (Quarterly) | 343.00M |
| Total Expenses (Quarterly) | 221.00M |
| EPS Diluted (Quarterly) | 0.9839 |
| Gross Profit Margin (Quarterly) | 85.42% |
| Profit Margin (Quarterly) | 35.57% |
| Earnings Yield | 8.17% |
| Operating Earnings Yield | 12.18% |
| Normalized Earnings Yield | 10.35 |